We’re pleased to announce that in January 2019 a regular inspection of Good Manufacturing Practice was conducted by the State Institute for Drug Control in Prague. On the basis of their findings a GMP Certificate will be issued to the full extent of our authorization to manufacture medicinal products. The inspection report will also be provided to the US FDA under the MRA agreement (mutual recognition of GMP inspection results) between the US and EU. Quinta-Analytica is one of the first companies whose inspection report has been requested by the US FDA from the State Institute for Drug Control, and we’re honored to receive this recognition.“

Additional News

  • 5 srpna 2025

    Preclinical Bioanalysis That Accelerates Clinical Entry

    How fit-for-purpose and GLP-compliant bioanalysis can streamline your path to IND and CTA approvals.

  • 22 června 2023

    Quinta Analytica Partners with EvidentIQ to Enhance Efficiency of Phase 1 Studies

    EvidentIQ partners with Quinta-Analytica to enhance Phase 1 study efficiency

  • 15 června 2023

    Novavax & Conscio: Behind the Scenes of Vaccine Development

    Discover how the Conscio Group and renowned vaccine manufacturer Novavax collaborate behind the scenes to ensure quality and efficiency in vaccine production.